Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
Aim. To conduct a cost analysis of using novel inhibitors of P2Y 12 (prasugrel and ticagrelor) in patients with acute coronary syndrome (ACS) in the Russian healthcare system.Material and methods. The analysis was performed using the design of a comparative study of prasugrel and ticagrelor ISAR-REA...
Saved in:
| Main Authors: | I. N. Dyakov, E. A. Ushkalova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4063 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
by: Fadel Bahouth, et al.
Published: (2025-05-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01) -
P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01) -
Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)